Invokana and Actemra drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Invokana (canagliflozin) and Actemra (tocilizumab). Common drug interactions include oedema among females and pain among males.

The phase IV clinical study analyzes what interactions people have when they take Invokana and Actemra. It is created by eHealthMe based on reports of 33 people who take the same drugs from the FDA, and is updated regularly.

What is Invokana?

Invokana has active ingredients of canagliflozin. It is often used in diabetes. eHealthMe is studying from 29,937 Invokana users. Check the latest studies of Invokana.

What is Actemra?

Actemra has active ingredients of tocilizumab. It is often used in rheumatoid arthritis. eHealthMe is studying from 102,759 Actemra users. Check the latest studies of Actemra.

On Jul, 13, 2026

33 people who take Invokana and Actemra together, and have interactions are studied.

What are the common drug interactions of Invokana and Actemra, by gender? *:

female:

Oedema (fluid collection in tissue)
Pain
Scar
Skin disorder (skin disease)
Sleep apnoea syndrome (a sleep-related disorder in which the effort to breathe is diminished or absent)
Swelling
Blood pressure systolic increased
Sepsis (a severe blood infection that can lead to organ failure and death)
Fungal infection
Kidney infection

male:

Pain
Abdominal discomfort
Drug ineffective
Drug intolerance (drug sensitivity)
Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
Dyspepsia (indigestion)
Gastrointestinal infection (infection of stomach and intestine)
Hand deformity
Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue)
Hepatic fibrosis (scarring process that represents the liver's response to injury)

What are the common drug interactions of Invokana and Actemra, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Adverse drug reaction
Hospitalisation

40-49:

Fatigue (feeling of tiredness)
Nasopharyngitis (inflammation of the nasopharynx)
Blood pressure fluctuation
Abdominal pain upper
Bladder disorder
Blood pressure diastolic decreased
Blood pressure systolic decreased
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Constipation
Cough

50-59:

Sleep apnoea syndrome (a sleep-related disorder in which the effort to breathe is diminished or absent)
Swelling
Weight decreased
Agitation (state of anxiety or nervous excitement)
Arthralgia (joint pain)
Blood cholesterol increased
Body temperature decreased
Cardiac disorder
Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
Cough

60+:

Arthralgia (joint pain)
Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue)
Ear infection
Eyelid infection
Heart rate increased
Hypotension (abnormally low blood pressure)
Influenza
Malaise (a feeling of general discomfort or uneasiness)
Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves)
Neck pain

What are the existing conditions these people have? *

High Blood Pressure: 19 people, 57.58%
Oedema (fluid collection in tissue): 9 people, 27.27%
Inflammation: 9 people, 27.27%
High Blood Cholesterol: 9 people, 27.27%
Pain In Extremity: 4 people, 12.12%
Neck Pain: 4 people, 12.12%
Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 4 people, 12.12%
Joint Pain: 4 people, 12.12%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 6.06%
Psoriasis (immune-mediated disease that affects the skin): 2 people, 6.06%

* Approximation only. Some reports may have incomplete information.

Do you take Invokana and Actemra?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously